|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, November 04, 2009 ) New York, NY - MabCure did a pilot study looking at 13 patients with ovarian cancer—half of which went through chemotherapy. They examined the blood of these patients with the antibodies they discovered. The objective was to see if their antibodies could successfully find and “mark” any remaining cancer cells in the blood. However, according to the standard existing detection methods, these patients were in remission since they found no cancer cells left in their systems. The result stunned even skeptics. MabCure’s antibody detected cancer cells remaining in the the blood of all 13 patients. Every other test had missed them. This proves that their antibody was highly sensitive, extremely specific and accurate.
Another Study Confirmed Their Theory - 100% Accurate
MabCure then tested 30 patients with melanoma. One of their antibodies, designed specifically to find these particular cells, did so in 30 out of 30 patients. It correctly identified 100% of the different melanoma cells. They did what no other medical technology in the world could do.
Doctors are helpless when it comes to the very early detection of cancer. Using current methods, by the time they recognize the presence of cancer, depending on the kind it is, it is often too late. But when detected early, the survival rate skyrockets. This illness is only destructive if it progresses. The National Cancer Institute says, “Unfortunately, many cancers have no symptoms at early stages and are not detected until it is too late.”
MabCure is delivering on this need. The technology MabCure developed spots these problems earlier than an technology doctors have at their disposal today. ConsiderÂ…
• The New England Journal of Medicine says early detection is the key. “Patients whose cancers are detected in an early, localized stage have a 90% chance of surviving…”
• The Family Doctor Organization reveals that curing it can be easy. “If the tumor is found when it is still very small, curing the illness can be easy…”
• The University of Texas Anderson Cancer Center says you live a lot longer: “Early detection of cancer can greatly increase survival rates because it identifies cancer when it’s most treatable.”
• The World Health Organization (WHO) says your odds dramatically go up: “Finding cancer early greatly increases the chances for successful treatment…”
• Focus On Healthy Aging reports great news: “…raise your chances of a cure with early detection…”
• The Fred Hutchinson Cancer Research Center says it can save your life: “Early detection of cancer saves lives…”
Becoming a Major Player in a Multi-Billion Dollar Market
MabCure Can Become a Major Player In a Market ThatÂ’s Estimated to Hit $22 Billion in Sales by 2010.
Just two years ago, the therapeutic antibodies market enjoyed industry-wide sales of $7.3 billion. This market is expected to grow by 30% annually and reach $22 billion by 2010. Cancer dominates this market because the rewards of success dwarf most other ventures on the planet. Chemistry World magazine correctly says, “Cancer is a huge market.” It is an unfortunate fact, but a fact nonetheless.
Disclosure: All material herein was prepared by Keros Capital Inc. (Keros) based upon information believed to be reliable. The information contained herein is not guaranteed by Keros to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Keros is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.keroscapital.com or mentioned herein. Keros has been compensated seven thousand five hundred dollars for this advertising effort. Keros may receive additional compensation for future advertisements. Keros affiliates, officers, directors and employees may own shares and may buy and sell additional shares of the company mentioned herein and may profit in the event those shares rise in value. Keros will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. Copyright 2007 by Keros Capital. All rights reserved. This publication or part thereof may not be duplicated or reprinted without the written permission of the Publisher. Facsimile including photocopy(s) is strictly forbidden, except for facsimile correspondence between Keros Capital. If this publication contravenes any securities laws and/or regulations, the securities regulations of the country will prevail. In this event, this publication must be discarded immediately. Anyone not wishing to receive future Keros Capital Investor Reports should email us at opt-out@keroscapital.com
MabCure Inc.
Jim Mav
908-464-1747
jimmav@keroscapital.com 
Source: EmailWire.com
|
|
|
|
